HK$97.30
1.09%
Hong Kong, Oct 05, 04:08 pm HKT. Closed.
ISIN
KYG4818G1010
Symbol
1801
Index

Innovent Biologics Stock price

HK$96.25
-5.55 5.45% 1M
+4.75 5.19% 6M
+20.00 26.23% YTD
-4.45 4.42% 1Y
+58.00 151.63% 3Y
+21.95 29.54% 5Y
+79.67 480.52% 10Y
+79.67 480.52% 20Y
Hong Kong, Closing price Fri, Oct 02 2026
-1.80 1.84%
ISIN
KYG4818G1010
Symbol
1801
Index
Industry

Is Innovent Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$171.1b
Enterprise Value
HK$150.4b
Net debt
positive
Cash
HK$23.4b
Shares outstanding
1.7b
Valuation
P/E
120.3
P/S | estimate
9.3 | 7.7
EV/Sales | estimate
8.2 | 6.8
EV/FCF | ex SBC
- | -
P/B
7.1
Financial Health
Equity Ratio
51.8%
Return on Equity
4.2%
ROCE
5.4%
ROIC
10.7%
Debt/Equity
0.1
Financials
Revenue | estimate
HK$18.4b | HK$22.1b
EBITDA
-
EBIT
HK$2.0b
Net Income
HK$1.4b
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
37.5% | 45.1%
EBITDA
-
EBIT
27.8%
Net Income
8.8%
Free Cash Flow
-
Margin
Gross
85.9%
EBITDA
-
EBIT
11.0%
Net
7.9%
Free Cash Flow | ex SBC
- | -
More
EPS
HK$0.8
FCF per Share
-
Short interest
-
Employees
8k
Rev per Employee
HK$2.0m

Innovent Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

38 Analysts have issued a Innovent Biologics forecast:

35x Buy
92%
3x Hold
8%

Analyst Opinions

38 Analysts have issued a Innovent Biologics forecast:

Buy
92%
Hold
8%

Financial data from Innovent Biologics

Jun '26
+/-
%
18,383 18,383
38% 38%
100%
- Direct Costs 2,597 2,597
36% 36%
14%
15,786 15,786
38% 38%
86%
- Selling and Administrative Expenses 8,840 8,840
32% 32%
48%
- Research and Development Expense 3,861 3,861
56% 56%
21%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 2,022 2,022
28% 28%
11%
Net Profit 1,442 1,442
9% 9%
8%

In millions HKD.

Don't miss a Thing! We will send you all news about Innovent Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innovent Biologics Stock News

Positive
Reuters
●
3 months ago
Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' ​experimental autoimmune disease treatment in a deal worth ‌up to about $1.1 billion, the companies said on Tuesday.
Positive
Reuters
●
3 months ago
Innovent Biologics ​has entered ‌into an agreement that ​grants ​it sole commercialization ⁠rights for ​Eli Lilly's ​breast cancer drug Verzenios in ​mainland ​China, the Chinese drugmaker ‌said ⁠Tuesday.
Positive
Reuters
●
3 months ago
Pfizer's GLP-1 ​drug Ecnoglutide ‌and Innovent Biologics' ​mazdutide injection ​have passed a ⁠preliminary ​review to ​be potentially included in China's ​basic ​medical insurance drug catalogue, ‌a ⁠a list published by ​the ​National ⁠Healthcare Security Administration ​showed ​on ⁠Monday.
More Innovent Biologics News

Company Profile

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.

Head office China
CEO Dr. Yu
Employees 7,502
Website www.innoventbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today